본문 바로가기
KERD
논문KCI 등재

Tryptophan Hydroxylase 2 유전자다형성과 항정신병약물로 유발된 지연성운동장애의 연관성

Association Study between Tryptophan Hydroxylase 2 Gene -703G/T Polymorphism and Tardive Dyskinesia

김석주|박영민|김린|강승걸|이종훈|이헌정
대한조현병학회 (Korean Academy of Schizophrenia)|2012.06|대한조현병학회지 (Korean Journal of Schizophrenia Research)|제15권 제1호|pp. 34-38

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

지연성운동장애·Tryptophan hydroxylase 2 유전자·조현병Tardive dyskinesia · Tryptophan hydroxylase 2 gene · Schizophrenia
주제분류정신과학

초록

Objectives : Tardive dyskinesia (TD) is a serious and sometimes irreversible adverse effect that may develop during long-term antipsychotics treatment. Previous studies have suggested that brain serotonergic systems are related to TD vulnerability and tryptophan hydroxylase (TPH) is the rate limiting enzyme in the biosynthesis of serotonin. This study aimed to investigate the association between TPH2 gene -703G/T polymorphism (rs4570625) and antipsychotic-induced TD in the Korean schizophrenia patients. Methods : We investigated whether TPH2 gene -703G/T polymorphism is associated with antipsychotic-induced TD in 280 Korean schizophrenia patients. The subjects with TD (n=105) and without TD (n=175) were matched for antipsychotic drug exposure and other relevant variables. Results : There was no significant difference in the distribution of genotypic (χ2=3.00, p=0.223) and allelic (χ2=0.19, p=0.661) frequencies between patients group with TD and without TD. There was no significant difference in total Abnormal Involuntary Movement Scale score (F=1.95, p=0.362) among the genotype groups, either. Conclusions : The present study does not support that TPH2 gene -703G/T polymorphism is involved in TD of the Korean schizophrenia subjects.

Abstract

Objectives : Tardive dyskinesia (TD) is a serious and sometimes irreversible adverse effect that may develop during long-term antipsychotics treatment. Previous studies have suggested that brain serotonergic systems are related to TD vulnerability and tryptophan hydroxylase (TPH) is the rate limiting enzyme in the biosynthesis of serotonin. This study aimed to investigate the association between TPH2 gene -703G/T polymorphism (rs4570625) and antipsychotic-induced TD in the Korean schizophrenia patients. Methods : We investigated whether TPH2 gene -703G/T polymorphism is associated with antipsychotic-induced TD in 280 Korean schizophrenia patients. The subjects with TD (n=105) and without TD (n=175) were matched for antipsychotic drug exposure and other relevant variables. Results : There was no significant difference in the distribution of genotypic (χ2=3.00, p=0.223) and allelic (χ2=0.19, p=0.661) frequencies between patients group with TD and without TD. There was no significant difference in total Abnormal Involuntary Movement Scale score (F=1.95, p=0.362) among the genotype groups, either. Conclusions : The present study does not support that TPH2 gene -703G/T polymorphism is involved in TD of the Korean schizophrenia subjects.

참고문헌 (48)

  1. Jeste DV, "Tardive dyskinesia", Schizophr Bull, 19, pp.303~315 (1993)
  2. Kane JM, "Tardive dyskinesia: prevalence, incidence, and risk factors", J Clin Psychopharmacol, 8, pp.52~56 (1988)
  3. Tarsy D, "Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?", Mov Disord, 21, pp.589~598 (2006)
  4. Tamminga CA, "Neuroleptic- induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains", Psychopharmacology (Berl), 102, pp.474~478 (1990)
  5. Yassa R, "Familial tardive dyskinesia", Am J Psychiatry, 138, pp.1618~1619 (1981)
  6. Tarsy D, "The pathophysiologic basis of tardive dyskinesia", Biol Psychiatry, 12, pp.431~450 (1977)
  7. Hsieh CJ, "Genetic variability in serotonin receptor and transporter genes may influence risk for tardive dyskinesia in chronic schizophrenia", Psychiatry Res, 188, pp.175~176 (2011)
  8. Casey DE, "gamma-Acetylenic GABA in tardive dyskinesia", Arch Gen Psychiatry, 37, pp.1376~1379 (1980)
  9. Andreassen OA, "Neurotoxicity associated with neuroleptic- induced oral dyskinesias in rats. Implications for tardive dyskinesia?", Prog Neurobiol, 61, pp.525~541 (2000)
  10. Lee HJ, "Genetics of tardive dyskinesia", Int Rev Neurobiol, 98, pp.231~264 (2011)
  11. Meltzer HY, "The role of serotonin in antipsychotic drug action", Neuropsychopharmacology, 21, pp.106~115 (1999)
  12. Schillevoort I, "Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports", Int Clin Psychopharmacol, 17, pp.75~79 (2002)
  13. Sandyk R, "L-tryptophan in neuroleptic- induced tardive dyskinesia", Int J Neurosci, 42, pp.127~130 (1988)
  14. Basile VS, "Potkin SG, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia", Mol Psychiatry, 6, pp.230~234 (2001)
  15. Segman RH, "Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia", Mol Psychiatry, 6, pp.225~229 (2001)
  16. Tan EC, "Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor", Biol Psychiatry, 50, pp.144~147 (2001)
  17. Herken H, "Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene", Eur Psychiat, 18, pp.77~81 (2003)
  18. Chong SA, "Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese", Am J Med Genet, 96, pp.712~715 (2000)
  19. Kim YK, "Effect of serotonin-related gene polymorphisms on pathogenesis and treatment response in korean schizophrenic patients", Behav Genet, 41, pp.709~715 (2011)
  20. Zill P, "Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study", J Psychiatr Res, 41, pp.168~173 (2007)
  21. Patel PD, "Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland", Biol Psychiatry, 55, pp.428~433 (2004)
  22. De Luca V, "Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia", Psychopharmacology (Berl), 183, pp.378~382 (2005)
  23. Lin YM, "Association of functional polymorphisms of the human tryptophan hydroxylase 2 gene with risk for bipolar disorder in Han Chinese", Arch Gen Psychiatry, 64, pp.1015~1024 (2007)
  24. Lopez VA, "Nested association between genetic variation in tryptophan hydroxylase II, bipolar affective disorder, and suicide attempts", Biol Psychiatry, 61, pp.181~186 (2007)
  25. Al-Janabi I, "Association study of serotonergic gene variants with antipsychotic-induced adverse reactions", Psychiatr Genet, 19, pp.305~311 (2009)
  26. Segman RH, "Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia", Pharmacogenomics J, 3, pp.277~283 (2003)
  27. Kim YK, "A tryptophan hydroxylase 2 gene polymorphism is associated with panic disorder", Behav Genet, 39, pp.170~175 (2009)
  28. Han OS, "Structured Clinical Interview for DSM-IV Axis I Disorder-Korean Version" (2000), Hana Medical Publishing
  29. Lee HJ, "No association between dopamine D4 receptor gene - 521 C", T polymorphism and tardive dyskinesia in schizophrenia, 200707, pp.55, 47~51
  30. Lee HJ, "No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and post-traumatic stress disorder", Stress and Health, 22, pp.115~119 (2006)
  31. Lee HJ, "No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia", Hum Psychopharmacol, 22, pp.501~504 (2007)
  32. Kang SG, "No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1545~1548 (2008)
  33. Kang SG, "Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1844~1847 (2008)
  34. Kang SG, "Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia", NEUROPSYCHOBIOLOGY, 57, pp.22~25
  35. Kang SG, "Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia", Hum Psychopharmacol, 24, pp.55~60 (2009)
  36. Young-Min Park, "No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients", PSYCHIATRY INVESTIGATION, 8(1), pp.49~54 (2011), 대한신경정신의학회
  37. Guy W., "Abnormal Involuntary Movement Scale (AIMS), In ECDEU assessment manual for psychopharmacology. Rev. ed", pp.534~537 (1976), U.S. Dept. of Health, Education, and Welfare
  38. Schooler NR, "Research diagnosis for tardive dyskinesia", Arch Gen Psychiatry, 39, pp.486~487 (1982)
  39. Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
  40. Yoon HK, "TPH2 -703G", T SNP may have important effect on susceptibility to suicidal behavior in major depression, 2009, pp.33, 403~409
  41. Lerer B, "Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype", Int J Neuropsychopharmacol, 8, pp.411~425 (2005)
  42. Al Hadithy AF, "Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.475~481 (2009)
  43. Wilffert B, "The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX", J Psychopharmacol, 23, pp.652~659 (2009)
  44. Segman RH, "Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility", Psychopharmacology (Berl), 152, pp.408~413 (2000)
  45. Zhang ZJ, "Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia", Mol Psychiatry, 7, pp.670~671 (2002)
  46. Deshpande SN, "Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India", Psychiatr Genet, 15, pp.157~158 (2005)
  47. Rietschel M, "Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor", Neuroreport, 8, pp.1999~2003 (1997)
  48. Han GR, "A Korean population study of the nine STR loci FGA, VWA, D3S1358, D18S51, D21S11, D8S1179, D7S820, D13S317 and D5S818", Int J Legal Med, 114, pp.41~44 (2000)

이 간행물의 다른 논문 (6건)

Schizoaffective DisorderAndreas Marnerospp. 5-12조현정동장애와 정신증적 양상을 동반한 기분장애를 어떻게 구별할 수 있나?오근영, 양종철, 김형태, 박태원, 정영철, 황광표, 박철현, 은홍배pp. 13-19대만성 조현병 환자에서 12주 체중관리 프로그램이 삶의 질에 미치는 영향제영묘, 이대수, 박숙현, 김재진, 최진혁pp. 20-26조현병에서 긍정 정서가 인지적 갈등 해결에 미치는 영향과 사회적 무쾌감증과의 관계박일호, 김재진, 전지원, 김어수, 박재섭pp. 27-33조현병, 조현정동장애 외래 환자들의 대사증후군 유병률이화영, 최정은pp. 39-45
원문 보기